Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb24306 alone and with atezolizumab in advanced solid tumors
NL-OMON56429Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of efbalropendekin alfa and atezolizumab in Nonhematologic neoplasms (2 arms), sponsored by Genentech. Primary endpoints: Incidence and severity of adverse events, Change from baseline in targeted vital signs and 2 more. Started Jun 2021; status: recruiting.
02
Drugs
efbalropendekin alfaatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON56429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56429.